1. Pink Sheet
  2. >>Geography
  3. >>Europe

England’s Innovative Medicines Fund: Opportunities & Risks

 
• By Francesca Bruce

England’s Innovative Medicines Fund could make the UK a more attractive launch market following Brexit, but companies must also consider the risks of the fund.

Early morning sky background, sunlight through white clouds and free birds flying away
England's new Innovative Medicines Fund Offers New Possibilities For Promising New Medicines • Source: Shutterstock

England’s new £340m ($428m) Innovative Medicines Fund (IMF) offers new and earlier opportunities for companies to achieve market access where once they may have failed. However, companies should give careful consideration to both the potential advantages and risks of entering the fund, including the costs of gathering additional data, advised Caroline Hall, director of global market access & support at AmerisourceBergen’s Xcenda, a health care consultancy.

Launched in June, the fund will operate as a managed access fund along the lines of England’s interim funding mechanism, the Cancer Drugs Fund (CDF), to provide conditional reimbursement to...

Together the two funds will have a fixed budget of £680m a year. NICE, England’s health technology appraisal (HTA) institute, will now have an additional option if it chooses to...

More from Europe

How Pharma Companies Can Mitigate The Impact Of US Tariffs On The Supply Chain

 
• By Ewan Townsend

If US tariffs on pharmaceutical supply chain products come into force they could be disruptive for companies. Ewan Townsend, of the international law firm Arnold & Porter, explains how companies can mitigate issues through negotiating with suppliers and reallocating tariff responsibilities.

EMA Touts Faster Global Post-Approval Changes Via Regulatory Reliance

 
• By Eliza Slawther

The European Medicines Agency says that a regulatory reliance pilot that it is supporting to speed up assessments of post-approval changes appears to be accelerating evaluation timelines in non-EU countries.

UK And US Regulators In Sync On RWD External Control Arms

 
• By Vibha Sharma

The UK regulator’s draft guideline on the use of external control arms based on real-world data reflects concepts similar to those outlined by the US Food and Drug Administration.

New EU Approvals

 
• By Neena Brizmohun

The Pink Sheet's list of EU centralized approvals of new active substances has been updated to include two new products, one of which is Vyjuvek, Krystal Biotech's advanced therapy for treating dystrophic epidermolysis bullosa.

More from Geography

How Pharma Companies Can Mitigate The Impact Of US Tariffs On The Supply Chain

 
• By Ewan Townsend

If US tariffs on pharmaceutical supply chain products come into force they could be disruptive for companies. Ewan Townsend, of the international law firm Arnold & Porter, explains how companies can mitigate issues through negotiating with suppliers and reallocating tariff responsibilities.

Japan Price Cuts For Epkinly and Lunsumio Following CEA

 
• By Lisa Takagi

Japan is cutting more drug reimbursement prices following cost effectiveness analysis and is applying the methodology to a new group of products including Wegovy and Leqembi.